Patents by Inventor Jingrong Cui

Jingrong Cui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Urea peptoid boric acid compound, pharmaceutical composition thereof, preparation method therefor, and uses thereof
    Patent number: 10494384
    Abstract: The present invention provides a urea peptidomimetic boronic compound and pharmaceutical compositions thereof, their preparative methods and uses. The compounds are represented by the following formula (I).
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: December 3, 2019
    Assignees: Peking University, Zhengzhou Granlen Pharmatech. Ltd.
    Inventors: Runtao Li, Haoyun An, Liqiang Han, Zemei Ge, Jingrong Cui, Tieming Cheng
  • UREA PEPTOID BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USES THEREOF
    Publication number: 20180298036
    Abstract: The present invention provides a urea peptidomimetic boronic compound and pharmaceutical compositions thereof, their preparative methods and uses. The compounds are represented by the following formula (1).
    Type: Application
    Filed: September 22, 2016
    Publication date: October 18, 2018
    Inventors: Runtao Li, Haoyun An, Liqiang Han, Zemei Ge, Jingrong Cui, Tieming Cheng
  • Tripeptide boronic acid or boronic ester, preparative method and use thereof
    Patent number: 9421237
    Abstract: The present invention discloses proteasome inhibitors of tripeptide boronic acids or boronic esters represented by Formula (I), preparative method and use thereof. The proteasome inhibitors are therapeutical agents for treating malignant tumor, various nervous system degenerative diseases, muscle cachexia or diabetes, wherein the malignant tumor is leukemia, gastric cancer, hepatocarcinoma or nasopharyngeal carcinoma.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: August 23, 2016
    Assignee: PEKING UNIVERSITY
    Inventors: Runtao Li, Jingrong Cui, Yongqiang Zhu, Shuyang Yao, Zemei Ge, Tieming Cheng
  • HETEROARYL (ALKYL) DITHIOCARBAMATE COMPOUNDS, PREPARATION METHODS AND USES THEREOF
    Publication number: 20130136794
    Abstract: Heteroaryl(alkyl)dithiocarbamate compounds represented by general formula (I) or their pharmaceutically acceptable salts, their preparing methods, and their uses for preparing antitumor medicines are disclosed, wherein each said substituent is defined as in the description. The compounds are new tyrosine kinase inhibitors useful as an anti-tumor agents, preferably useful in the preparation of medicines for treating breast cancer, liver cancer, non-small cell lung cancer, gastric cancer, colon cancer, leukaemia or nasal cancer.
    Type: Application
    Filed: April 21, 2011
    Publication date: May 30, 2013
    Applicant: PEKING UNIVERSITY
    Inventors: Runtao Li, Zemei Ge, Jingrong Cui, Xingyl Sun, Zhongqing Wang, Xu Yan
  • TRIPETIDE BORONIC ACID OR BORONIC ESTER, PREPARATIVE METHOD AND USE THEREOF
    Publication number: 20120135921
    Abstract: The present invention discloses proteasome inhibitors of tripeptide boronic acids or boronic esters represented by Formula (I), preparative method and use thereof. The proteasome inhibitors are therapeutical agents for treating malignant tumor, various nervous system degenerative diseases, muscle cachexia or diabetes, wherein the malignant tumor is leukemia, gastric cancer, hepatocarcinoma or nasopharyngeal carcinoma.
    Type: Application
    Filed: May 17, 2010
    Publication date: May 31, 2012
    Inventors: Runtao Li, Jingrong Cui, Yongqiang Zhu, Shuyang Yao, Zemei Ge, Tieming Cheng
  • Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
    Patent number: 7250417
    Abstract: The present invention relates to compounds of the Formulae (I)-(IV), wherein R1-R6, R11-R13, X and Y are defined herein, and their pharmaceutically acceptable salts.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: July 31, 2007
    Assignee: Sugen Inc.
    Inventors: Jingrong Cui, Iriny Botrous
  • Aminoheteroaryl compounds as protein kinase inhibitors
    Publication number: 20070072874
    Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.
    Type: Application
    Filed: November 14, 2006
    Publication date: March 29, 2007
    Inventors: Jingrong Cui, Dilip Bhumralkar, Iriny Botrous, Ji Chu, Lee Funk, Cathleen Hanau, G. Harris, Lei Jia, Joanne Johnson, Stephen Kolodziej, Pei-Pei Kung, Xiaoyuan Li, Jason Lin, Jerry Meng, Mitchell Nambu, Christopher Nelson, Mason Pairish, Hong Shen, Michelle Tran-Dube, Allison Walter, Fang-Jie Zhang, Jennifer Zhang
  • Triazolotriazine compounds and uses thereof
    Patent number: 7122548
    Abstract: The present invention relates to compounds of the Formula (I), and their pharmaceutically acceptable salts.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: October 17, 2006
    Assignee: Sugen, Inc.
    Inventors: Fang-Jie Zhang, Tomas Vojkovsky, Ping Huang, Congxin Liang, Steven Huy Do, Marcel Koenig, Jingrong Cui
  • Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors
    Patent number: 7105562
    Abstract: The present invention relates to certain sulfonamido-substituted geometrically restricted indolinones of the formula: wherein R1–R12 and X are variables defined herein. The sulfonamido-substituted geometrically restricted indolinones of the preferred embodiments of the present invention modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: September 12, 2006
    Assignee: Sugen, Inc.
    Inventors: Fang-Jie Zhang, Jingrong Cui, Chung Chen Wei, Peng Cho Tang
  • Aminoheteroaryl compounds as protein kinase inhibitors
    Publication number: 20060178374
    Abstract: Aminoheteroaryl compounds are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
    Type: Application
    Filed: August 26, 2005
    Publication date: August 10, 2006
    Inventors: Jingrong Cui, Lee Funk, Lei Jia, Pei-Pei Kung, Jerry Meng, Mitchell Nambu, Mason Pairish, Hong Shen, Michelle Tran-Dube
  • Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
    Publication number: 20060128724
    Abstract: Compounds of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
    Type: Application
    Filed: August 26, 2005
    Publication date: June 15, 2006
    Inventors: Jingrong Cui, Lee Funk, Lei Jia, Pei-Pei Kung, Jerry Meng, Mitchell Nambu, Mason Pairish, Hong Shen, Michelle Tran-Dube
  • 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
    Patent number: 7053086
    Abstract: The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases (“PKs”), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: May 30, 2006
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Chung Chen Wei, Ping Huang, Jingrong Cui
  • Tetracyclic compounds as c-Met inhibitors
    Patent number: 7037909
    Abstract: The present invention relates to compounds of the Formulae (I) and (II), wherein R1-R10 and G are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.
    Type: Grant
    Filed: June 29, 2004
    Date of Patent: May 2, 2006
    Assignee: Sugen, Inc.
    Inventors: Tomas Vojkovsky, Marcel Koenig, Fang-Jie Zhang, Jingrong Cui
  • Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
    Publication number: 20060046991
    Abstract: Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
    Type: Application
    Filed: August 26, 2005
    Publication date: March 2, 2006
    Inventors: Jingrong Cui, Lee Funk, Lei Jia, Pei-Pei Kung, Jerry Meng, Mitchell Nambu, Mason Pairish, Hong Shen, Michelle Tran-Dube
  • Indolinone hydrazides as c-Met inhibitors
    Publication number: 20060009493
    Abstract: The present invention relates to compounds of the formulae (I)-(XII), wherein R1-R71, A, B, X, Y, G, L and Z are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.
    Type: Application
    Filed: June 25, 2004
    Publication date: January 12, 2006
    Inventors: Marcel Koenig, Jingrong Cui, Chung Wei, Steven Do, Fang-Jie Zhang, Tomas Vojkovsky, John Ramphal, Guang Yang, Matthew Mattson, Christopher Nelson, Peng Tang
  • 4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors
    Patent number: 6908930
    Abstract: This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1 and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, X, Y, and Z are defined herein. The invention further relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.
    Type: Grant
    Filed: July 21, 2003
    Date of Patent: June 21, 2005
    Assignee: Sugen, Inc.
    Inventors: Congxin Liang, Li Sun, Chung Chen Wei, Peng Cho Tang, Gerald McMahon, Klaus Peter Hirth, Jingrong Cui
  • Arylmethyl triazolo-and imidazopyrazines as c-Met inhibitors
    Publication number: 20050107391
    Abstract: The present invention relates to compounds of the Formulae (I)-(IV), wherein R1-R6, R11-R13, X and Y are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.
    Type: Application
    Filed: June 25, 2004
    Publication date: May 19, 2005
    Inventors: Jingrong Cui, Iriny Botrous
  • Triazolotriazine compounds and uses thereof
    Publication number: 20050075340
    Abstract: The present invention relates to compounds of the Formula (I), and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.
    Type: Application
    Filed: June 24, 2004
    Publication date: April 7, 2005
    Inventors: Fang-Jie Zhang, Tomas Vojkovsky, Ping Huang, Congxin Liang, Steven Do, Marcel Koenig, Jingrong Cui
  • 4-aryl substituted indolinones
    Patent number: 6861418
    Abstract: The present invention relates to 4-arylindolinones, as well as pharmaceutical compositions thereof, capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. The present invention also relates to methods for treating protein kinase related disorders.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: March 1, 2005
    Assignee: Sugen, Inc.
    Inventors: Jingrong Cui, Ruofei Zhang, Hong Shen, Ji Yu Chu, Fang-Jie Zhang, Marcel Koenig, Steven Huy Do, Xiaoyuan Li, Chung Chen Wei, Peng Cho Tang
  • Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors
    Publication number: 20050038066
    Abstract: The present invention relates to certain sulfonamido-substituted geometrically restricted indolinones of the formula: wherein R1-R12 and X are variables defined herein. The sulfonamido-substituted geometrically restricted indolinones of the preferred embodiments of the present invention modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Application
    Filed: August 5, 2004
    Publication date: February 17, 2005
    Inventors: Fang-Jie Zhang, Jingrong Cui, Chung Chen Wei, Peng Tang